Abiopharma

TEMPUS AI, INC. (TEM)

Symbol	TEM
Name	TEMPUS AI, INC.
Sector	TECHNOLOGY
Region	North America
Industry	Computer Software: Programming, Data Processing
Address	600 WEST CHICAGO AVENUE,SUITE 510, CHICAGO, Illinois, 60654, United States
Telephone	+1 800 - 976-5448
Fax	—
Email	—
Website	https://www.tempus.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001717115
Description	Tempus AI endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world. We have launched a suite of different products derived from our Platform, which have gained significant traction over the past five years. To date, our offerings have been used by approximately 95% of the largest public pharmaceutical companies. Additional info from NASDAQ: Tempus AI endeavors to unlock the true power of precision medicine by creating Intelligent Diagnostics through the practical application of artificial intelligence in healthcare. Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal. To accomplish this, we built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Our proprietary technology has allowed us to amass what we consider to be one of the largest libraries of clinical and molecular oncology data in the world. We have launched a suite of different products derived from our Platform, which have gained significant traction over the past five years. To date, our offerings have been used by approximately 95% of the largest public pharmaceutical companies.

2026-07-20 21:15

(99% Neutral) TEMPUS AI, INC. (TEM) Announces Business Combination

2026-07-08 20:15

Fukushima Ryan 🔴 sold 10.0K shares of Tempus AI, Inc. (TEM) at $60.00 Transaction Date: Jul 06, 2026 | Filing ID: 000018

2026-06-30 00:40

Doudna Jennifer A 🔴 sold 2.7K shares of Tempus AI, Inc. (TEM) at $55.00 Transaction Date: Jun 25, 2026 | Filing ID: 000006

2026-06-30 00:40

Rogers James William 🔴 sold 11.5K shares of Tempus AI, Inc. (TEM) at $55.00 Transaction Date: Jun 25, 2026 | Filing ID: 000016

2026-06-29 21:52

📋 Eric Lefkofsky (Officer) plans to sell 166K shares of Tempus AI, Inc. (at $56.14 each, total $9.3M) Filed: Jun 29, 2026 | ID: 000669

2026-06-25 20:25

📋 JAMES ROGERS (Officer) plans to sell 12K shares of Tempus AI, Inc. (at $51.94 each, total $599K) Filed: Jun 25, 2026 | ID: 006505

2026-06-25 12:30

Tempus Announces Research Collaboration with Angiosarcoma Awareness, Inc. to Uncover Insights on Rare Cancers

2026-06-11 12:30

Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

2026-06-09 10:00

Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

2026-06-05 20:01

Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference